Mineralocorticoid replacement therapy in salt‐wasting congenital adrenal hyperplasia
Clinical Endocrinology · 2024-10 · 101 (4) · 346-358
DOI: 10.1111/cen.14959 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Endocrinology, online erschienen am 11.08.2023. Verfasst von Katharina Lang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology in Charlottenburg, Berlin, Germany. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Mineralocorticoids, Hormone Replacement Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Patients with salt‐wasting congenital adrenal hyperplasia (SW‐CAH) usually show pronounced impairment of aldosterone secretion and, therefore, also require mineralocorticoid replacement. While a lot of research and discussion focusses on the glucocorticoid therapy in SW‐CAH to replace the missing cortisol and to control adrenal androgen excess, very little research is dealing with mineralocorticoid replacement. However, recent data demonstrated an increased cardiovascular risk in adult CAH patients urging to reflect also on the current mineralocorticoid replacement therapy. In this review, we explain the role and function of the mineralocorticoid receptor, its ligands and inhibitors and its relevance for the therapy of patients with SW‐CAH. We performed an extensive literature search and present data on mineralocorticoid therapy in SW‐CAH patients as well as clinical advice how to monitor and optimise mineralocorticoid replacement therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology in Charlottenburg, Berlin, Germany.
- Department of Endocrinology and Metabolism, Charite-Universitätsmedizin, Campus Mitte, Berlin, Germany.
Zitieren
APA
Lang, K., Quinkler, M., & Kienitz, T. (2024). Mineralocorticoid replacement therapy in salt‐wasting congenital adrenal hyperplasia. Clinical Endocrinology, 101(4), 346-358. https://doi.org/10.1111/cen.14959
Vancouver
Lang K, Quinkler M, Kienitz T. Mineralocorticoid replacement therapy in salt‐wasting congenital adrenal hyperplasia. Clinical Endocrinology. 2024;101(4):346-358. doi:10.1111/cen.14959
BibTeX
@article{Lang2024,
author = {Lang, Katharina and Quinkler, Marcus and Kienitz, Tina},
title = {Mineralocorticoid replacement therapy in salt‐wasting congenital adrenal hyperplasia},
journal = {Clinical Endocrinology},
year = {2024},
volume = {101},
number = {4},
pages = {346--358},
doi = {10.1111/cen.14959}
}
EUVIMED